Anti-SARS-CoV-2, Biosimilar of Therapeutic Antibody

CATALOG NUMBER: SCV2-BeMab, 50 µg

Introduction	The novel coronavirus (SARS-CoV-2), previously called 2019-nCoV, is a newly identified coronavirus causing the ongoing outbreak of atypical pneumonia in Wuhan China from late 2019. The genome of SARS-CoV-2 has 89% nucleotide identity with bat SARS-like-CoVZXC21 and 82% with that of human SARS-CoV. The phylogenetic trees of their orf1a/b, Spike, Envelope, Membrane and Nucleoprotein also clustered closely with those of the bat, civet and human SARS coronaviruses. However, the external subdomain of Spike's receptor binding domain (RBD) of SARS-CoV-2 shares only 40% amino acid identity with other SARS-related coronaviruses.
Description	Human monoclonal anti-SARS-CoV-2 antibody, purified from mammalian cell culture supernatant.
Applications	Biosimilar of an FDA approved therapeutic antibody (LY-CoV1404 or LY3853113); for research use only.
Specificity	Binding and neutralizing activity with reported SARS-CoV-2 variants of concern, including Omicron and the subvariants
Clonality	Monoclonal
Isotype	IgG1-lambda 2
Purification	Protein A/G chromatography
Purity	>95%
Storage	Store at -20 °C; Stable for 6 months from the date of shipment when kept at 4 °C. Non-hazardous.
Concentration	1 mg/ml in PBS, pH7.5



Figure 1. Inhibition of Infectivity assay using SARS-CoV-2 614D pseudoviral particles and HEK293-ACE2 cells with different amount of SCV2-BeMab, 70 nM, 0.7 nM, and 7 pM.

For research use only. Not suitable for clinical or therapeutic use.